Clinical Trials & Research Studies Near You (Updated 6/25)

Genetic Studies of Insulin and Diabetes

NCT00001987

Recruiting

The study will allow researchers to obtain blood, plasma, DNA, and RNA for genetic studies of insulin. There will be a focus on the causes of insulin resistance and diabetes mellitus. Insulin is a hormone found in the body that controls the level of sugar in the blood. Insulin resistance refers to conditions like diabetes when insulin does not work properly. In this study researchers would like to compare patients with diabetes and other forms of insulin resistance to normal individuals. The stu... Read More

Gender:

ALL

Ages:

Between 6 months and 120 years

Trial Updated:

05/17/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diabetes Mellitus, Severe Insulin Resistance

Register for Updates

Learn More ›

Lidocaine Versus Bupivacaine in Orthognathic Surgery

NCT06450028

Recruiting

In this research study, we want to learn more about the impact of two different local anesthetics (bupivacaine and lidocaine) on patient experience following orthognathic (jaw) surgery. Both anesthetics are within the standard of care for dental and orthognathic procedures, but can vary in how quickly they take action and how long they last. This study will provide us with a greater understanding of how anesthetic choice affect patient outcomes, and how we can strive to make these outcomes as fa... Read More

Gender:

ALL

Ages:

Between 15 years and 35 years

Trial Updated:

05/17/2025

Locations: Boston Children's Hospital, Boston, Massachusetts

Conditions: Pain, Postoperative, Numbness, Temperature Sensation, Perception of Touch

Register for Updates

Learn More ›

Diagnosis of Pheochromocytoma

NCT00004847

Recruiting

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surge... Read More

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surgery, general anesthesia or childbirth. Patients with pheochromocytoma may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Study participants will undergo blood, urine, and imaging tests, described below, to detect pheochromocytoma. If a tumor is found, the patient will be offered surgery. If surgery is not feasible (for example, if there are multiple tumors that cannot be removed), evaluations will continue in follow-up visits. If the tumor cannot be found, the patient will be offered medical treatment and efforts to detect the tumor will continue. Main diagnostic and research tests may include the following: 1. Blood tests - mainly measurements of plasma or urine catecholamines and metanephrines as well as methoxytyramine. If necessary the clonidine suppression test can be carried out. 2. Standard imaging tests - Non-investigational imaging tests include computed tomography (CT), magnetic resonance imaging (MRI), sonography, and 123I-MIBG scintigraphy and FDG (positron emission tomography) PET/CT. These scans may be done before and/or after surgical removal of pheochromocytoma. 3. Research PET scanning is done using an injection of radioactive compounds. Patients may undergo 18F-FDOPA, 18F-DA, as well as 68Ga-DOTATATE PET/CT . Each scan takes up to about 2 hours. 4. Genetic testing - A small blood sample is collected for DNA analysis and other analyses. Read Less

Gender:

ALL

Ages:

Between 3 years and 120 years

Trial Updated:

05/17/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Pheochromocytoma, Endocrine Disease, Endocrine Diseases

Register for Updates

Learn More ›

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

NCT06635629

Recruiting

Background: Cushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol. Excess cortisol can cause serious issues, such as diabetes, high blood pressure, weight gain, and mood changes. Diagnosing CS early can be difficult. One test used to diagnose CS, the desmopressin (Desmo) stimulation test (DesmoST), has not been studied in enough people to know how accurate it is. Ob... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/17/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Cushing Syndrome

Register for Updates

Learn More ›

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437

Recruiting

Background: - The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections. These infections are often difficult to treat. Researchers want to collect blood and tissue samples from people who have unusual, persistent or severe fungal infections or immune problems that increase the risk of these infections. Objectives: - To collect medical information and samples for a long-term st... Read More

Gender:

ALL

Ages:

Between 1 day and 99 years

Trial Updated:

05/16/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED

Register for Updates

Learn More ›

Parkinson's Foundation PD GENEration Genetic Registry

NCT04994015

Recruiting

Development of a central repository for PD-related genomic data for future research.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +55 locations

University of Alabama Birmingham, Birmingham, Alabama

MD First Research, Chandler, Arizona

Barrow Neurological Institute, Phoenix, Arizona

University of Arkansas, Fayetteville, Arkansas

University of California San Diego (UCSD), La Jolla, California

University of California Los Angeles, Los Angeles, California

University of California San Francisco (UCSF), San Francisco, California

University of Colorado Anschutz, Aurora, Colorado

Hartford Healthcare, Hartford, Connecticut

Aventura Neurology - Visionary Investigators Network, Aventura, Florida

Parkinson's Disease & Movement Disorder Center of Boca Raton, Boca Raton, Florida

University of Florida, Gainesville, Florida

University of Miami, Miami, Florida

Cleveland Clinic Weston, Weston, Florida

Morehouse College, Atlanta, Georgia

The Queen's Health System, Honolulu, Hawaii

University of Illinois-Chicago, Chicago, Illinois

Rush University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Northwestern University, Evanston, Illinois

Indiana University, Indianapolis, Indiana

University of Iowa, Iowa City, Iowa

University of Kansas, Lawrence, Kansas

University of Kentucky, Lexington, Kentucky

Louisiana State University, Shreveport, Louisiana

Johns Hopkins, Baltimore, Maryland

University of Maryland, College Park, Maryland

Massachusetts General Hospital (MGH), Boston, Massachusetts

BMC Community Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts

Struthers Parkinson's Center - HealthPartners Park Nicollet, Golden Valley, Minnesota

Rutgers University, New Brunswick, New Jersey

University of New Mexico, Albuquerque, New Mexico

New York University, New York, New York

Mount Sinai, New York, New York

Columbia University, New York, New York

University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Atrium Health, Charlotte, North Carolina

University of Cincinnati, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

Cleveland Clinic, Cleveland, Ohio

Ohio State University, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Vanderbilt University, Nashville, Tennessee

Baylor College of Medicine, Houston, Texas

University of Texas at San Antonio, San Antonio, Texas

Intermountain Health, Murray, Utah

Virginia Commonwealth University, Richmond, Virginia

Evergreen Health, Kirkland, Washington

Inland Northwest Research, Spokane, Washington

Medical College of Wisconsin, Milwaukee, Wisconsin

Toronto Western Hospital, Toronto, Ontario

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Conditions: Parkinson's Disease

Register for Updates

Learn More ›

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899

Recruiting

The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: University of Alabama Hospital, Birmingham, Alabama +89 locations

University of Alabama Hospital, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic, Phoenix, Arizona

UC San Diego Moores Cancer Center, La Jolla, California

University of California Los Angeles (UCLA), Los Angeles, California

Stanford Cancer Institute, Palo Alto, California

Colorado Blood Cancer Institute, Denver, Colorado

Moffitt Cancer Center, Tampa, Florida

Georgia Cancer Center at Augusta University, Augusta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

University of Iowa, Iowa City, Iowa

The University of Kansas Hospital, Westwood, Kansas

Norton Cancer Institute, St. Matthews Campus, Shelbyville, Kentucky

Ochsner Clinic Foundation, New Orleans, Louisiana

University of MD Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester, Minnesota

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Weill Cornell Medical College - NewYork Presbyterian Hospital, New York, New York

Columbia University Medical Center, New York, New York

University of Rochester Medical Center, Rochester, New York

Novant Health Cancer Institute- Hematology, Charlotte, North Carolina

Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Prisma Health Cancer Institute, Greenville, South Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

Tennessee Oncology, PLLC, Nashville, Tennessee

Henry-Joyce Cancer Center, Nashville, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

The University of Texas, MD Anderson Cancer Center, Houston, Texas

Intermountain LDS Hospital/Blood and Marrow Transplant/ Acute Leukemia Program, Salt Lake City, Utah

Virginia Commonwealth University, Richmond, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Royal Prince Alfred Hospital, Camperdown, New South Wales

Royal Brisbane and Women's Hospital, South Brisbane, Queensland

Peter MacCallum Cancer Center, Melbourne, Victoria

Medizinische Universität Innsbruck, Innsbruck, Not set

Zuniklinikum Salzburg, Landeskrankenhaus, Universitatsklinik fur Innere Medizin III der PMU, Salzburg, Not set

Universitätsklinikum St. Pölten, St. Poelten, Not set

Medizinische Universität Wien (AKH Wien, Medical University Vienna and General Hospital Vienna), Vienna, Not set

Jewish General Hospital, Montreal, Not set

The Ottowa Hospital- General Campus, Ottawa, Not set

Princess Margaret Cancer Centre, Toronto, Not set

CHU Bordeaux-Hopital Haut-Leveque, Bordeaux, Not set

Centre Leon Berard, Cedex Lyon 08, Not set

CHU Dijon, Dijon, Not set

Hopital Claude Huriez CHU Lille, Service Maladies du sang, Lille cedex, Not set

Hopital Saint Eloi, Montpellier CEDEX 05, Not set

Centre Hospitalier Universitaire de Nice, Nice, Not set

Hopital Henri MONDOR, APHP, Paris, Not set

CHU Pontchaillou, Rennes CEDEX, Not set

Centre Hospitalier Universitaire(CHU) de Toulouse, Toulouse, Not set

Helios Klinikum Berlin-Buch, Berlin, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Universitätsklinikum bonn, medizinische klinik III, Bonn, Not set

Uniklinikum Duesseldorf, Klinik fuer Haematologie, Onkologie und klinische Immunologie, Duesseldorf, Not set

Universitätsklinik Erlangen, Erlangen, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Not set

ASST Degli Spedali Civili di Brescia, Brescia, Not set

Ospedale San Raffaele, Milano, Not set

Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia, Perugia, Not set

Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Not set

Universita Cattolica del Sacro Cuore, Rome, Not set

IRCCS Istituto Clinico Humanitas, Rozzano, Not set

University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Not set

Tohoku University Hospital, Miyagi, Not set

Osaka University Hospital, Osaka, Not set

Juntendo University Hospital, Tokyo, Not set

Tokyo Metropolitan Komagome Hospital, Tokyo, Not set

Academisch Medisch Centrum, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Leiden University Medical Center, Leiden, Not set

Maastricht Universitair Medisch Centrum, Maastricht, Not set

Universitair Medisch Centrum Utrecht, Utrecht, Not set

Centro Hospitalar Universitario Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia de Lisboa Francisco Gentil - E.P.E., Lisbon, Not set

Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto, Not set

Institut Catala d'Oncologia, Barcelona, Not set

Hospital Universitari Vall D'Hebron, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Marqués de Valdecilla, Santander, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

Addenbrookes Hospital (Cambridge University Hospitals NHS Foundation Trust), Birmingham, Not set

University Hospitals Southampton, Southampton, Not set

Conditions: High-risk Large B-cell Lymphoma (LBCL)

Register for Updates

Learn More ›

SilverCloud as a School-Based Intervention for Vulnerable Youth

NCT06004414

Recruiting

The goal of this study is to test the efficacy and feasibility of a clinician-guided, app-based cognitive behavioral therapy (CBT) program, SilverCloud, as a school-based mental health intervention for vulnerable youth. An open trial of SilverCloud will be conducted to determine preliminary efficacy in this sample and inform program refinements by collecting outcome self-report assessments and conducting interviews on feasibility and acceptability. After the program and its implementation strate... Read More

Gender:

ALL

Ages:

Between 13 years and 22 years

Trial Updated:

05/16/2025

Locations: Rutgers University, New Brunswick, New Jersey +2 locations

Conditions: Depression, Anxiety

Register for Updates

Learn More ›

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

NCT06227026

Recruiting

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will utilize a staggered enrollment design with a safety observation period.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: Huntsman Cancer Institute, Salt Lake City, Utah

Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma

Register for Updates

Learn More ›

Endometrial Cell Collection With the PadKit

NCT06464107

Recruiting

All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: Jersey Shore University Medical Center, Neptune, New Jersey +1 locations

Conditions: Neoplasms

Register for Updates

Learn More ›

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320

Recruiting

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +46 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic, Phoenix, Arizona

City of Hope-Duarte, Duarte, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA, Los Angeles, California

UC San Diego Health Moores Cancer Center, San Diego, California

Mission Hall UCSF, San Francisco, California

Rocky Mountain Cancer, Aurora, Colorado

Mayo Clinic Cancer Center, Jacksonville, Florida

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

Cancer Care Centers of Brevard Inc, Palm Bay, Florida

The University of Chicago Medical Center, Chicago, Illinois

Johns Hopkins, Baltimore, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Washington University, Saint Louis, Missouri

Roswell Park Cancer Institute, Buffalo, New York

NYU Lagone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Columbia University Medical Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Stephenson Cancer Center, Oklahoma City, Oklahoma

Abramson Cancer Center Clinical Research Unit, Philadelphia, Pennsylvania

Sarah Cannon Research Institute (Tennessee), Nashville, Tennessee

Texas Oncology Sammons, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Texas Oncology - Central South, Irving, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Virginia Cancer Specialists, Fairfax, Virginia

Institut Paoli Calmettes, Marseille, Not set

Centre Eugene Marquis, Rennes, Not set

Hopital Paul Brousse, Villejuif, Not set

Gustave Roussy, Villejuif, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

IEO-Istituto Europeo di Oncologia, Milan, Not set

Azienda Ospedaliera, Pisa, Not set

Osaka International Cancer, Osaka, Not set

National Cancer Center Hospital, Tokyo, Not set

Cancer Institute Hospital of JFCR, Tokyo, Not set

Kanagawa Cancer Center, Yokohama, Not set

Pan-American Center for Oncology Trials, San Juan, Not set

Hospital Unversitari, Barcelona, Not set

Hospital 12 de Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Clinico de Valencia, Valencia, Not set

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Register for Updates

Learn More ›

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

NCT06898905

Recruiting

This study evaluates the feasibility and safety of a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: Yale University, New Haven, Connecticut

Conditions: Diffuse Large B-Cell Lymphoma

Register for Updates

Learn More ›

All Clinical Trials

Match to Clinical Trials